Commercial and medical affairs teams need precision pharmaceutical insights and actionable intelligence to make confident business decisions. The global pandemic has altered medical education (promo and certified) and conference execution, making hyper-targeting even more important. Also, medical affairs and commercial teams should be planning for the return of in-person conferences. Whilst the importance of conferences such as ASCO, ESMO, and ASH are acknowledged, this mantle is shared more than ever today.
ESMO’s importance, in particular, has grown significantly in recent years, both in terms of size and diversity of audience as well as its reach as a global platform (e.g. more US healthcare professionals following ESMO online). In 2018, ESMO attracted nearly 28,000 attendees from 137 countries and over 3,000 submitted abstracts compared to 16,000 attendees from 127, and just over 2,000 submitted abstracts from the 2012 ESMO conference.
There has also been a noticeable rise in the importance of highly targeted disease-focused conferences such as EHA, IASLC, ICML, increased number of breakout meetings under the auspices of ASCO and ESMO (focusing on one cancer), and other similar scientific conferences with their increased importance as a platform for the dissemination of new data, meetings, exchange and reach to a global audience.
Hyper-targeting the right audience
With this in mind, medical affairs and commercial teams need reliable agency partners with winning expertise and experience in healthcare market insights, who know what it takes to master these trends. In a highly competitive space where hyper-targeting is essential, MDoutlook gives medical affairs the right mix of agile assets, value solutions, and professional customer access to drive successful precision engagement with your most relevant customers in oncology, hematology, and rare diseases.
Case study: Driving impactful outcomes through precision intelligence
As an example, at the 2019 annual meeting of the Association of Residents in Radiation Oncology (ASTRO), one of our clients was interested in recruiting very specific radiation oncologists (recruited to a very tight inclusion criteria) to an event at the congress to gain a richer understanding of their practices in a number of different tumor-areas and to collect real-world evidence (RWE). The interactive workshops proved highly successful and delivered deeper pharmaceutical insights on the current practices of radiation-oncologists across indications to create value across functions (marketing, market access, and medical affairs). And during the current pandemic situation, we have continued the engagement for our clients through Lumineer™ (our digital intelligence and engagement platform) with equal success. For the future, we envision hybrid, customized solutions to be organized more befitting clients’ needs and criteria.
During the conference season, we have been particularly busy helping medical affairs and commercial teams gain valuable pharmaceutical insights into their data presentations – as well as measuring impact – as can be seen from post-ASCO articles (clinical impact of ASCO presentations covering integration-of-new-treatment-regimens-in-CLL; novel-targeted-agents-for-MNSCLC and what-will-happen-in-NMCRPC and MHSPC.) published in partnership with OBR earlier this Summer.
This work has included:
- Connecting clients to the right cliniicians and experts through our validated community of 140,000+ treaters and 14,000+ ThoughtLeaders.
- Answering tomorrow’s critical business questions today via DOCpulse™, our agile, adaptable and technology-driven solution.
- Experience and expertise of our team that has won client praise and high satisfaction through offering hyper-personalized and impactful solutions.
Meet us (digitally and hopefully in-person soon)
Whether you are assessing the impact of data announcements or have another healthcare market research project in mind that requires hyper-targeting of your professional customers, we can enable medical affairs and commercial teams to achieve their goals, utilizing our proprietary assets and access to the world’s largest verified community of 140,000+ clinicians and experts in oncology, hematology, and rare diseases. This community is enriched through physician self-reported characteristics, and external adapters that are carefully and meaningfully applied through machine-learning and AI.
Let’s take your next step together by arranging a virtual meeting to scope out your future success!
For further discussion or to arrange a meeting, please contact [email protected] or call +1 404.496.4136.